Dr. Ghosh on Unmet Needs With CAR T-Cell Therapy in DLBCL

Partner | Cancer Centers | <b>Atrium Health Levine Cancer Institute</b>

Nilanjan Ghosh, MD, PhD, director of the Lymphoma Program and a physician with Levine Cancer Institute, discusses unmet needs with CAR T-cell therapy in diffuse large B-cell lymphoma.

Nilanjan Ghosh, MD, PhD, director of the Lymphoma Program and a physician with Levine Cancer Institute, discusses unmet needs with CAR T-cell therapy in diffuse large B-cell lymphoma (DLBCL).

​CAR T-cell therapy has revolutionized the treatment of ​many hematologic malignancies, including aggressive B-cell malignancies,​ like DLBCL. However, despite the intrigue CAR T-cell therapy has garnered in recent years, unmet needs ​remain, Ghosh says.

Patients with DLBCL who relapse after CAR T-cell therapy generally have poor outcomes, Ghosh explains. In addition, toxicities associated with CAR T-cell therapy, including cytokine release syndrome and neurotoxicity​, limit the administration of the therapy to specialized centers.

Future research efforts should focus on mitigating the​se toxicities to improve the accessibility of CAR T-cell therapy for more patients, Ghosh concludes.